Inova Labs markets portable oxygen concentrators for patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD) or asthma. Portable oxygen concentrators like the LifeChoice® Activox can give patients their freedom back to engage in regular daily activities. Gilde actively supports the international marketing and sales activities of Inova Labs.

There are 13 million people diagnosed with COPD in the United States alone. Portable oxygen concentrators like the LifeChoice® Activox can give patients their freedom back to engage in regular daily activities.

Gilde joined the Series B growth stage financing of Inova Labs in 2011 and then led the Series C financing in 2013. Over the period of the investment, Inova Labs quadrupled sales, launched two new products and expanded gross margins before its acquisition by ResMed in January 2016. Gilde played an active role in the development of the company as member of the board, on the Audit Committee, as well as during the sale of the company to ResMed.